Zobrazeno 1 - 10
of 80
pro vyhledávání: '"365"'
Publikováno v:
Annals of the Rheumatic Diseases. 73:780.1-780
Background In most patients, gout is caused by inefficient excretion of uric acid, resulting in hyperuricemia and the formation of crystal deposits of uric acid. The renal uric acid transporter URAT1 (SLC22A12) is important for regulating serum uric
Publikováno v:
Annals of the Rheumatic Diseases. 81:914-915
BackgroundSeveral population-based cohort studies have reported an increased risk of venous thromboembolism (VTE) in gout patients. However, none of these studies has investigated the temporal relationship between gout flares and VTE.ObjectivesTo exp
Autor:
Harris A. Ahmad, Thomas Fuerst, Mette Østergaard, Sean E. Connolly, S. Du, C. Pachai, C. Wu, P.G. Conaghan, Paul Bird, J. Landis
Publikováno v:
Annals of the Rheumatic Diseases. 80:794-794
Background:The semi-quantitative Outcome Measures in Rheumatology (OMERACT) Psoriatic Arthritis Magnetic Resonance Imaging Score (PsAMRIS) was developed for the evaluation of inflammatory and destructive changes in PsA,1 but has limited trial usage.O
Autor:
G. F. Ferraccioli, R. Caporali, Alberto Cauli, Francesco Paolo Cantatore, Marco Sebastiani, Ennio Giulio Favalli, Giovanni Lapadula, Rosario Foti, Maurizio Rossini, Roberto Gorla, Carlomaurizio Montecucco, Florenzo Iannone, Fabrizio Conti, Elisa Gremese, Enrico Fusaro
Publikováno v:
Annals of the Rheumatic Diseases. 80:582.1-582
Background:Long-term observational data on the real-life use of JAK inhibitors (JAKis) for rheumatoid arthritis (RA) and their comparison with biological drugs are still very limited. Large population-based registries have been increasingly used to i
Autor:
Jasvinder A. Singh, Shaohua Yu
Publikováno v:
Annals of the Rheumatic Diseases. 76:72-78
ObjectiveTo assess the effect of allopurinol use on the risk of incident atrial fibrillation (AF) in the elderly.MethodsWe used the 5% random Medicare Claims data from 2006 to 2012 to examine the association of allopurinol use and incident AF in a co
Autor:
R. Wong, Hendrika Bootsma, Marleen Nys, Neelanjana Ray, Sumanta Mukherjee, Tsutomu Takeuchi, Raphaèle Seror, Jacques-Eric Gottenberg, Gary N. Foulks, Takayuki Sumida, E. William St. Clair, Alan N. Baer
Publikováno v:
Annals of the Rheumatic Diseases, 80(3), 339-348. BMJ PUBLISHING GROUP
Annals of the Rheumatic Diseases
Annals of the Rheumatic Diseases
ObjectivesTo evaluate efficacy and safety of abatacept in adults with active primary Sjögren’s syndrome (pSS) in a phase III, randomised, double-blind, placebo-controlled trial.MethodsEligible patients (moderate-to-severe pSS [2016 ACR/European Le
Publikováno v:
Annals of the Rheumatic Diseases. 75:70.2-70
Background The SRI(4) is a composite endpoint used in SLE clinical trials. A post-hoc analysis of two Phase III studies of belimumab1 showed that the achievement of an SRI(4) response at 52 weeks is associated with clinically meaningful benefits, irr
Autor:
Philip Brohawn, S. Yoo, M Khamashta, L. Wang, Kenneth C. Kalunian, Victoria P. Werth, Richard Furie, Joan T. Merrill, G. Illei, Jorn Drappa
Publikováno v:
Annals of the Rheumatic Diseases. 75:168.1-168
Background Increased activity of the type I interferon (IFN) pathway is central to the pathogenesis of SLE. Blocking the type I receptor may reduce SLE activity more effectively than inhibiting IFN-α alone. Objectives Efficacy and safety of anifrolu
Publikováno v:
Annals of the Rheumatic Diseases. 74:537.1-537
Background Gout is caused by chronic hyperuricemia, leading to uric acid deposition. Humans and apes have relatively high serum uric acid (sUA) levels due to inactivating mutations in the enzyme uricase which took place during hominid evolution, prev
Autor:
Christopher Morehouse, Lorin Roskos, Brandon W. Higgs, Philip Brohawn, Yihong Yao, Gabriel Robbie, B. Zheng
Publikováno v:
Annals of the Rheumatic Diseases. 74:946.2-946
Background Sifalimumab is a fully human, IgG 1 κ monoclonal antibody in Phase IIb clinical development for systemic lupus erythematosus (SLE). Sifalimumab binds to and neutralizes the majority of IFN-α subtypes. Objectives We assessed the pharmacok